News Release(2013)
2013
-
December 24, 2013
Kissei Announces Licensing Agreement with Pfizer Inc. for KUX-1151, a Novel Investigational Therapy for Gout and Hyperuricemia
-
October 17, 2013
Kissei and Kyorin announce the initiation of a Phase I clinical trial of KEA-0447/KRP-EPA605 for the treatment of overactive bladder
-
September 30, 2013
Conclusion of an Agreement about Long-Acting Erythropoiesis Stimulating Agent.
-
September 13, 2013
Approval of Partial Changes of Indication of Glufast® in Japan
-
January 30, 2013
New Drug Application submitted for "Dexrazoxane" for the Treatment of Anthracycline Extravasation in Japan